Cite

    Nyström, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2017). novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes, obesity & metabolism, 19(6), 831–841. http://access.bl.uk/ark:/81055/vdc_100046457466.0x00001d